RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Randomized, Prospective Trial of Customized Neoadjuvant versus Standard Chemotherapy Gets Underway
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 3
SP 14
OP 14
DO 10.1177/155989771403009
UL http://mdc.sagepub.com/content/14/3/14.abstract
AB The first prospective, multicenter, randomized Phase 2 study to test the use of customized chemotherapy (CT) in locally advanced stage IIIA (N2) non—small cell lung cancer (NSCLC) is currently recruiting patients. The rationale and design of the Customized Neoadjuvant Versus Standard Chemotherapy in NSCLC Patients With Resectable Stage IIIA (N2) Disease trial [CONTEST; NCT01784549] were presented in a poster session.